Codexis (NASDAQ: CDXS) has announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform.
According to Codexis, the agreement builds on advances presented at TIDES USA 2026, where, for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis.
Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality.
In a statement, Alison Moore, PhD., president and CEO of Codexis, commented, “This agreement is an important next step in bringing our latest ECO Synthesis capabilities to a customer. Working with a pioneer in the siRNA field offers an exciting opportunity to demonstrate how ECO Synthesis can deliver stereochemical control, which may offer both superior product quality and therapeutic performance to an innovator’s pipeline over assets produced using traditional solid phase chemistry methods.”
